The effectiveness of ovulation induction using hMG in women with polystic ovarian syndrome

Abstract

The aim of this study was to assess the effectiveness and safety of a low-dose step-up protocol with a hMG starting dose of 75 IU for ovulation induction in patients with polycystic ovary syndrome (PCOS). In this retrospective study, 299 PCOS patients who received hMG for ovulation induction combined with either IUI or intercourse in 2013 at IVFAS, were recruited. Patients were administered hMG 75IU per day for 6 days, the dose was then increased by 75 IU every 6 days if there was no follicle of >12 mm diameter (maximum 150 IU/day). Human Chorionic Gonadotrophin (5,000IU) or GnRH agonist (triptoreline 0.2mg) was administered when the leading follicle was ≥18 mm, and the patients had intrauterine insemination or natural intercourse in 36 h later. Average age of women was 28.6 (years). duration of stimulation was 13.2 ± 3.7 days and mean total hMG dose was 1202 ± 506 IU. A developing follicle was observed in 96.3% of cycles, of which 56.7% had unifollicular development and 4.3% were referred to IVM/IVF due to over-response. The clinical pregnancy rate was 46.9%. There were 22 out of 148 pregnancies (14.9%) were multiple pregnancies, including 2 triplets. There were only 4 cases of mild ovarian hyperstimulation syndrome. A low-dose step-up protocol with hMG of 75 IU/day is effective and safe in ovulation induction for pcos patients.